---
marp: true
theme: default
paginate: true
footer: "PHA 548 â€¢ Nonbenzodiazepine Sedative-Hypnotics â€¢ MedChem Focus"
style: |
  section {
    font-family: Helvetica, sans-serif;
    font-size: 20px;
    text-align: left;
    padding: 40px;
  }
  h1 { font-size: 40px; }
  h2 { font-size: 30px; margin-bottom: 15px; }
  h3 { font-size: 24px; margin-top: 20px; }
---

# ðŸŒ™ Lecture 02  
## Medicinal Chemistry of Non-Benzodiazepine Sedative-Hypnotics  
**Z-Drugs & Other Alternative Hypnotics**

Course: PHA 548 Pharmacology & Medicinal Chemistry  
Instructor: Sidney Bolden, Jr., Ph.D.

---

## ðŸŽ¯ Learning Objectives

By the end of this session, students will be able to:

1ï¸âƒ£ Compare non-BZD pharmacophores vs classical benzodiazepines *(Bloom: Understand)*  
2ï¸âƒ£ Evaluate SAR determining selectivity for **Î±1** GABA\_A subunits *(Bloom: Analyze)*  
3ï¸âƒ£ Predict duration of hypnotic effect based on metabolic liabilities *(Bloom: Analyze)*  
4ï¸âƒ£ Relate specific structural motifs to avoidance of active metabolites *(Bloom: Apply)*  

---

## Why â€œZ-Drugsâ€ Were Invented

- **BZD issues:**  
  â€¢ Active metabolites â†’ long duration  
  â€¢ Residual morning sedation  
  â€¢ Cognitive impairment, abuse potential

- **Z-drug design goals:**  
  âœ” Maintain hypnotic efficacy  
  âœ” Shorter half-life  
  âœ” Less receptor promiscuity  
  âœ” Less next-day impairment

---

## ðŸ”¬ Non-BZD BZD-Site Pharmacophore

Key binding interactions (no diazepine ring required):

| Region | Role |
|-------|-----|
| Aromatic ring | Ï€-stacking like BZD C-ring |
| H-bond acceptor (carbonyl/urea) | Anchors at BZD site |
| Lipophilic tail | Occupies hydrophobic subpocket |

Primary **Î±1** receptor subtype preference â†’ **sedation predominates** over anxiolysis.

---

## ðŸ§ª Zolpidem â€” Imidazopyridine Class

**Structure Features**
- Imidazopyridine core mimics spatial arrangement of BZD rings  
- **p-Cl phenyl** â†’ lipophilicity + affinity  
- Amide â†’ H-bond acceptor
  
![Z_Drug](figures/zolpidem.jpg)


**PK**
- CYP3A4 metabolism â†’ **inactive metabolites**
- tÂ½ ~ 2â€“3 h â†’ **sleep onset**

![Z_Drug_met](figures/zolpidem_metabolism.jpg)


**MedChem Takeaway**
Short lipophilic scaffold â†’ rapid distribution & clearance.

---

## ðŸ§ª Zaleplon â€” Pyrazolopyrimidine Class

**Structure**
- Heteroaromatic core  
- Nitrile group tunes electronics


![Z_Drug_2](figures/zaleplon.jpg)

**Metabolism**
- Major: **aldehyde oxidase**  
- No active metabolites  
- **tÂ½ ~ 1 h â†’ ultra-short**


![Z_Drug_met_2](figures/zaleplon_metabolism.jpg)


**Clinical**
- Middle-of-night dosing possible  
- Minimal morning sedation

---

## ðŸ§ª Eszopiclone â€” Cyclopyrrolone Class

**Structural Concepts**
- S-enantiomer â†’ pharmacologic activity  
- Lactam carbonyl anchors receptor  
- More polar than zolpidem â†’ **longer** duration (5â€“7 h)

![Z_Drug_3](figures/eszopicolone.jpg)


![Z_Drug_met_3](figures/eszopicolone_metabolism.jpg)

**Adverse effect**
- Distinct: dysgeusia (metallic taste)
  


---

## SAR Patterns to Know (EXAM)

| Change | Result |
|-------|--------|
| â†‘ Lipophilicity | â†‘ onset, â†‘ next-day effects |
| Block oxidative metabolism | â†‘ duration |
| Add bulky para-substituent | â†“ receptor fit â†’ inactive |
| Short, polar scaffold | Short duration, cleaner profile |

---

## Non-BZD Non-GABA Hypnotic Example

### **Doxepin** (Low-dose H1 antagonist)
- Tricyclic structure â†’ **long** acting  
- High-anticholinergic potential if higher doses used  
- **Not** acting at BZD site

---

## Quick Clinical Compare

| Feature | Z-Drugs | Benzodiazepines |
|--------|---------|----------------|
| Target | BZD site (Î±1-favored) | BZD site (mixed Î±1/2/3/5) |
| Duration | Short | Variable to long |
| Active metabolites | Rare | Frequent |
| Amnesia | Lower | Higher |

---

## Active Learning â€“ Predict PK

> Add a **3-OH** to eszopiclone:  
âœ” Faster glucuronidation  
âœ” Shorter duration  
âœ˜ Reduced sleep maintenance role

*(Bloom: Apply â€” iRAT/Think-Pair-Share)*

---

## Summary

- Structure, metabolism, subunit selectivity drive **duration + safety**  
- Z-drugs â‰  BZDs structurally  
- Less cognitive disruptionâ€¦ but still controlled substances (C-IV)

---

## Assessment Mapping

| Learning Objective | Bloom | Item Type |
|------------------|------|-----------|
| 1 | Understand | MCQ recognition |
| 2 | Analyze | SAR MCQ image items |
| 3 | Analyze | PK prediction cases |
| 4 | Apply | Structure modification reasoning |

---

# Questions?
